Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 18F-AV-45 Clear all
Terminated Phase 4 Interventional Results available

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 1, 2026, 4:50 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Entire-body PET Scans for Multiple Sclerosis

NCT04390009
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Entire-body PET-CT scans, Amyvid radiopharmaceutical
Diagnostic Test · Drug
Lead sponsor
Brain Health Alliance
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ladera Ranch, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 1, 2026, 4:50 PM EDT
Terminated Phase 4 Interventional Results available

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

NCT03333551
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F18 Florbetapir (amyvid) cardiac PET/CT imaging
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 1, 2026, 4:50 PM EDT
Terminated Not applicable Interventional

Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid

NCT02343757
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
PET/MRI
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

NCT02759887
View directory record Official record
Conditions
Down Syndrome, Alzheimer's Dementia
Interventions
biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy
Procedure · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 1, 2026, 4:50 PM EDT
Active, not recruiting No phase listed Observational

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

NCT02951598
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

NCT01834716
View directory record Official record
Conditions
Alzheimer's Disease Prevention
Interventions
Aerobic vs. Non-Aerobic exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 1, 2026, 4:50 PM EDT
Recruiting Not applicable Interventional

Molecular Imaging of Primary Amyloid Cardiomyopathy

NCT02641145
View directory record Official record
Conditions
Amyloidosis, Primary, Cardiomyopathy
Interventions
F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET
Radiation · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

NCT00855868
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, [11C]-PIB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

NCT00857532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2013 · Synced Sep 1, 2026, 4:50 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

NCT01826110
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[11C]PIB
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03080051
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
Interventions
[18F]MNI-952, [18F]Florbetapir
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Healthy Volunteers
Interventions
[18F]MNI-1126
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Reader Training Processes

NCT02051790
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Sep 1, 2026, 4:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

NCT02266563
View directory record Official record
Conditions
Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment
Interventions
Amyvid PET Scan, T807 PET scan
Drug
Lead sponsor
Samuel Gandy
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Sep 1, 2026, 4:50 PM EDT
Active, not recruiting Phase 4 Interventional

Effects of Brain Beta-Amyloid on Postoperative Cognition

NCT01606488
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction
Interventions
Florbetapir F 18 (18F-AV-45), no intervention
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

NCT01565291
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • North East, Maryland • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Florbetapir Calibration to the Centiloid Scale

NCT02120664
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Florbetapir (18F), 11C-PiB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 1, 2026, 4:50 PM EDT
Completed No phase listed Observational

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials

NCT02918539
View directory record Official record
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
florbetapir F 18 PET scan
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
75
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

NCT00857415
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 1, 2026, 4:50 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

NCT03641768
View directory record Official record
Conditions
Alzheimer Dementia, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
MRI, PET, 18F-Florbetapir, Radioligand 18F-AV-1451
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 1, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers

NCT03902548
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]P16-129
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 1, 2026, 4:50 PM EDT